I Kurilova1,2,3, A Gonzalez-Aguirre1, R G Beets-Tan2, J Erinjeri1, E N Petre1, M Gonen4, M Bains5, N E Kemeny6, S B Solomon1, C T Sofocleous7. 1. Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 2. Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 3. GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7. Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. sofoclec@mskcc.org.
Abstract
PURPOSE: To review outcomes following microwave ablation (MWA) of colorectal cancer pulmonary metastases and assess predictors of oncologic outcomes. METHODS: Technical success, primary and secondary technique efficacy rates were evaluated for 50 patients with 90 colorectal cancer pulmonary metastases at immediate, 4-8 weeks post-MWA and subsequent follow-up CT and/or 18F-FDG PET/CT. Local tumor progression (LTP) rate, LTP-free survival (LTPFS), cancer-specific and overall survivals were assessed. Complications were recorded according to SIR classification. RESULTS: Median follow-up was 25.6 months. Median tumor size was 1 cm (0.3-3.2 cm). Technical success, primary and secondary technique efficacy rates were 99, 90 and 92%, respectively. LTP rate was 10%. One-, 2- and 3-year LTPFS were: 93, 86 and 86%, respectively, with median LTPFS not reached. Median overall survival was 58.6 months, and median cancer-specific survival (CSS) was not reached. One-, 2- and 3-year overall and CSS were 94% and 98, 82 and 90%, 61 and 70%, respectively. On univariate analysis, minimal ablation margin (p < 0.001) and tumor size (p = 0.001) predicted LTPFS, with no LTP for minimal margin ≥ 5 mm and/or tumor size < 1 cm. Pleural-based metastases were associated with increased LTP risk (p = 0.002, SHR = 7.7). Pre-MWA CEA level > 10 ng/ml (p = 0.046) and ≥ 3 prior chemotherapy lines predicted decreased CSS (p = 0.02). There was no 90-day death. Major complications rate was 13%. CONCLUSIONS: MWA with minimal ablation margin ≥ 5 mm is essential for local control of colorectal cancer pulmonary metastases. Pleural-based metastases and larger tumor size were associated with higher risk of LTP. CEA level and pre-MWA chemotherapy impacted CSS.
PURPOSE: To review outcomes following microwave ablation (MWA) of colorectal cancer pulmonary metastases and assess predictors of oncologic outcomes. METHODS: Technical success, primary and secondary technique efficacy rates were evaluated for 50 patients with 90 colorectal cancer pulmonary metastases at immediate, 4-8 weeks post-MWA and subsequent follow-up CT and/or 18F-FDG PET/CT. Local tumor progression (LTP) rate, LTP-free survival (LTPFS), cancer-specific and overall survivals were assessed. Complications were recorded according to SIR classification. RESULTS: Median follow-up was 25.6 months. Median tumor size was 1 cm (0.3-3.2 cm). Technical success, primary and secondary technique efficacy rates were 99, 90 and 92%, respectively. LTP rate was 10%. One-, 2- and 3-year LTPFS were: 93, 86 and 86%, respectively, with median LTPFS not reached. Median overall survival was 58.6 months, and median cancer-specific survival (CSS) was not reached. One-, 2- and 3-year overall and CSS were 94% and 98, 82 and 90%, 61 and 70%, respectively. On univariate analysis, minimal ablation margin (p < 0.001) and tumor size (p = 0.001) predicted LTPFS, with no LTP for minimal margin ≥ 5 mm and/or tumor size < 1 cm. Pleural-based metastases were associated with increased LTP risk (p = 0.002, SHR = 7.7). Pre-MWA CEA level > 10 ng/ml (p = 0.046) and ≥ 3 prior chemotherapy lines predicted decreased CSS (p = 0.02). There was no 90-day death. Major complications rate was 13%. CONCLUSIONS: MWA with minimal ablation margin ≥ 5 mm is essential for local control of colorectal cancer pulmonary metastases. Pleural-based metastases and larger tumor size were associated with higher risk of LTP. CEA level and pre-MWA chemotherapy impacted CSS.
Authors: Tito Livraghi; Luigi Solbiati; Franca Meloni; Tiziana Ierace; S Nahum Goldberg; G Scott Gazelle Journal: Cancer Date: 2003-06-15 Impact factor: 6.860
Authors: Michel Gonzalez; Antoine Poncet; Christophe Combescure; John Robert; Hans Beat Ris; Pascal Gervaz Journal: Ann Surg Oncol Date: 2012-10-28 Impact factor: 5.344
Authors: Wolf Bäumler; Lukas Philipp Beyer; Lukas Lürken; Philipp Wiggermann; Christian Stroszczynski; Marco Dollinger; Andreas Schicho Journal: Diagnostics (Basel) Date: 2022-04-14
Authors: Kaisa Lehtomäki; Hanna P Stedt; Emerik Osterlund; Timo Muhonen; Leena-Maija Soveri; Päivi Halonen; Tapio K Salminen; Juha Kononen; Raija Kallio; Annika Ålgars; Eetu Heervä; Annamarja Lamminmäki; Aki Uutela; Arno Nordin; Juho Lehto; Tiina Saarto; Harri Sintonen; Pirkko-Liisa Kellokumpu-Lehtinen; Raija Ristamäki; Bengt Glimelius; Helena Isoniemi; Pia Osterlund Journal: Cancers (Basel) Date: 2022-03-28 Impact factor: 6.639
Authors: Valentina Vespro; Maria Chiara Bonanno; Maria Carmela Andrisani; Anna Maria Ierardi; Alice Phillips; Davide Tosi; Paolo Mendogni; Sara Franzi; Gianpaolo Carrafiello Journal: Tomography Date: 2022-03-01
Authors: Janani S Reisenauer; Patrick W Eiken; Matthew R Callstrom; Geoffrey B Johnson; Karlyn Pierson; Bettie Lechtenberg; Shanda H Blackmon Journal: J Thorac Dis Date: 2022-04 Impact factor: 2.895
Authors: Felix G Gassert; Johannes Rübenthaler; Clemens C Cyran; Johann S Rink; Vincent Schwarze; Johanna Luitjens; Florian T Gassert; Marcus R Makowski; Stefan O Schoenberg; Marius E Mayerhoefer; Dietmar Tamandl; Matthias F Froelich Journal: Eur J Nucl Med Mol Imaging Date: 2021-03-09 Impact factor: 9.236